Alumis Inc.
ALMS
Rang în acțiuni
#10397
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Preț acțiune
$6.15
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$795.38M
Schimbare (1 zi)
-2.61%
Schimbare (1 an)
170.70%
Țară
US
Tranzacționează Alumis Inc. (ALMS)
Categorie
Healthcare
EPS pentru Alumis Inc. (ALMS)
EPS la data de March 2025 TTM: $-2.70
Conform celor mai recente rapoarte financiare și prețului acțiunilor Alumis Inc., EPS-ul actual al companiei (TTM) este $-2.70. La sfârșitul anului 2023, compania avea un EPS de $-5.43 o creștere față de EPS-ului din 2022, care a fost de $-0.70.
Istoricul EPS pentru Alumis Inc. din 2021 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
